Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a
DURHAM, N.C., May 26, 2021 /PRNewswire/ -- Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients. IN-006 is a potent, neutralizing monoclonal antibody being investigated for the treatment of COVID-19. Initial results of this study are expected in 2022. The Inhalon muco-trapping antibody platform directly traps the virus in airway mucus, preventing the local spread of the infection, and quickly eliminating the virus from the lungs through the body’s natural ability to clear mucus. Inhaled therapy can be readily self-administered by patients, extends critical drug supplies to more patients and does not place excessive demands on healthcare staff and infusion clinic space that IV drugs do. “Inhalon’s unique ‘muco-trapping’ inhaled antibody platform is ideally suited to quickly halt the COVID-19 infection by concentrating antibody therapy in the respiratory tract where the virus proliferates,” said John Whelan, president and chief executive officer, Inhalon Biopharma. “We are very pleased that USAMRDC has seen the potential in our breakthrough approach and chose to support our clinical studies, which we look forward to initiating this summer following productive discussions with the FDA.” “The USAMRDC assessed the merits of Inhalon’s novel technology and planned study as outstanding,” said William Howell, president, Medical Technology Enterprise Consortium. “We believe that Inhalon’s inhaled therapy offers many attractive benefits for patients and the healthcare system that are not available with intravenous or other systemically-dosed treatments.” The Inhalon inhaled antibody platform can fight a broad range of ARIs that currently have no treatments. In addition to the Phase 1/2a COVID-19 trial, Inhalon has preclinical programs for the treatment of the top two respiratory infections leading to hospitalization, respiratory syncytial virus (RSV) and metapneumovirus (MPV). About ARIs About Inhalon’s “Muco-trapping” Immunotherapy Platform About Inhalon About MTEC Company Contact: Media Contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/inhalon-biopharma-receives-7-million-from-usamrdc-to-study-inhaled-muco-trapping-antibody-for-the-treatment-of-covid-19-301299832.html SOURCE Inhalon Biopharma |